SF3B1 silencing rendered the T-ALL cell lines more sensitive to chemotherapeutic drugs than the control cells, confirming the impact of SF3B1 on the chemotherapeutic response (Fig. 5, E and F, and fig. The gene discussed is SF3B1; the disease is acute lymphoblastic leukemia.